WO2005112904A1 - ペルオキシソーム増殖剤応答性受容体(ppar)活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 - Google Patents
ペルオキシソーム増殖剤応答性受容体(ppar)活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 Download PDFInfo
- Publication number
- WO2005112904A1 WO2005112904A1 PCT/JP2005/009258 JP2005009258W WO2005112904A1 WO 2005112904 A1 WO2005112904 A1 WO 2005112904A1 JP 2005009258 W JP2005009258 W JP 2005009258W WO 2005112904 A1 WO2005112904 A1 WO 2005112904A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ppar
- group
- activator
- obesity
- diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- PPAR Peroxisome proliferator-activated receptor
- the present invention relates to a peroxisome proliferator-activated receptor (PPAR) activator, and a medicament, a supplement, a functional food and a food additive using the same.
- PPAR peroxisome proliferator-activated receptor
- TNF-fibrils and free fatty acids which inhibit glucose uptake in muscle cells and liver cells, as well as adiponectin, which promotes the action of insulin. It is suppressed, resulting in insulin resistance.
- PPAR which is a nuclear receptor
- PPARa is mainly expressed in liver cells, and is also expressed in cardiomyocytes and gastrointestinal tract cells, and is involved in fatty acid oxidation, ketone body formation, apolipoprotein formation, and the like.
- PPAR ⁇ has no tissue specificity and is expressed throughout the body, but is significantly expressed in colorectal cancer cells.
- PPAR y can be divided into two subtypes, ⁇ 1 and ⁇ 2, where y1 is expressed in adipose tissue, immune tissue, adrenal gland, and small intestine, and y2 is specific in adipocytes It plays an important role in the induction of adipocyte differentiation and lipogenesis.
- PPAR is greatly involved in improving insulin resistance. It is also said to be involved in improving insulin, type 2 diabetes, obesity, hypertension, hyperlipidemia and arteriosclerosis. From this point of view, PPAR-activating substances have been studied, for example, fibrates, thiazolidine derivatives, fatty acids, leukotriene B4, indomethacin, ibuprofen, phenoprofen, 15_deoxy_ ⁇ -12, 14-PGJ2 Synthetic PPAR activators are known. However, synthetic PPAR activators have the problem of side effects due to long-term ingestion and are not suitable for ingestion in daily life to prevent or ameliorate diseases such as insulin resistance.
- PPAR activators derived from natural ingredients such as curcumin contained in Japanese pepper, monoacylglycerol which is a kind of fat and oil, and catechins contained in tea etc. are reported as PPAR activators. (See, for example, Patent Document 1).
- PPAR activators derived from natural ingredients such as curcumin contained in Japanese pepper, monoacylglycerol which is a kind of fat and oil, and catechins contained in tea etc.
- the present invention has been made in view of such circumstances, and provides a PPAR activator that can be taken for a long period of time without the problem of side effects and has no problem even when added to foods or the like. , Its purpose.
- the PPAR activator of the present invention is characterized in that it contains ⁇ -thaliptoxanthine.
- the present inventors have conducted a series of studies on PPAR activators as natural components in order to solve the above-mentioned problems, and found that cryptoxanthin, which is abundantly contained in mandarin citrus fruits such as Unshu mandarin orange, is capable of The inventors have found that they have an effect, and have reached the present invention. That is, Satsuma mandarin orange containing a large amount of ⁇ cryptoxanthin has been consumed for many years, and its safety has been confirmed. In addition, ⁇ -cributoxanthin has a low caloric value, so that there is no problem even if a diabetic patient or an obese patient takes it for a long time.
- ⁇ -Taributan xanthine is tasteless and odorless and does not impair the flavor of the food even when added to foods, so it can be added to foods and taken daily for a long time. It will be possible. Therefore, according to the present invention, ⁇ -cributoxanthin activates PPAR, thereby promoting the burning of fat, suppressing the secretion of TNF_ and free fatty acids, and promoting the secretion of adiponectin. Can normalize adipocyte status, improve insulin resistance, and improve other symptoms such as hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity. These are effective not only for humans but also for other animals.
- FIG. 1 is a graph showing the PPAR ⁇ ligand activity of ⁇ cryptoxanthin in one example of the present invention.
- the PPAR activator of the present invention may contain other components such as other PPAR activators, in addition to j3-cryptoxanthin, in addition to the 3- / 3-tryptoxanthine. Is also good.
- the activated PPAR may be, for example, either PPAR ⁇ or PPAR ⁇ , but preferably both.
- PPAR activator of the present invention for example, minute ⁇ system of TNF alpha and free fatty acids in adipocytes, the secretion of adiponectin in adipocytes It has at least one action such as promotion and promotion of fat oxidation in liver cells. Further, the PPAR activator of the present invention has, for example, an action of inducing at least one of apoptosis, differentiation and miniaturization of adipocytes.
- the ⁇ -cributoxanthin used is not particularly limited, and may be, for example, those derived from citrus, persimmon, papaya, vegetation, and red pepper. is there. Among them, citrus is more preferred and is preferably derived from mandarin citrus
- ⁇ -cributoxanthin may be, for example, one isolated and purified from the above-mentioned citrus fruits, or a commercially available product.
- the medicament of the present invention comprises, for example, at least one disease selected from the group consisting of insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity.
- a medicament for preventing or treating the above which comprises the above-mentioned PPAR activator of the present invention.
- the medicament of the present invention may contain, for example, other PPAR activators and various additives in addition to the PPAR activator of the present invention.
- specific dosage forms include, for example, tablets, fine granules (including powders), capsules and liquids (including syrups).
- the medicament of the present invention can be produced according to a usual method described in the Japanese Pharmacopoeia and the like, by appropriately using a carotenoid and a base material suitable for each dosage form.
- the route of administration is not particularly limited, and includes, for example, oral administration and parenteral administration, and the parenteral administration includes, for example, oral administration, intratracheal administration, rectal administration, subcutaneous administration, and intramuscular administration. And intravenous administration.
- the supplement of the present invention comprises, for example, at least one supplement selected from the group consisting of insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis, and obesity.
- a supplement for preventing or ameliorating a disease the supplement comprising the activator of the present invention.
- the supplement of the present invention may contain, for example, other PPAR activators, various additives, and other supplements in addition to the PPAR activator of the present invention. Examples include various vitamins such as C, amino acids, and oligosaccharides.
- the form of the supplement of the present invention is not particularly limited, and examples thereof include tablets, fine granules (including powders), capsules and liquids (including syrups).
- the functional food of the present invention comprises at least one disease selected from the group consisting of insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity.
- the functional food of the present invention may contain, for example, other PPAR activators and various additives in addition to the PPAR activator of the present invention.
- the form of the functional food of the present invention is not particularly limited, and includes, for example, foods, confectioneries, functional drinks, and the like.
- the food additive of the present invention comprises at least one disease selected from the group consisting of insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis, and obesity. It is a food additive for preventing or ameliorating the disease, which is the food additive containing the PPAR activator of the present invention.
- the food additive of the present invention may contain, for example, other PPAR activators and various additives in addition to the PPAR activator of the present invention.
- the form of the food additive of the present invention is not particularly limited, and examples thereof include a liquid, a paste, a powder, a flake, and a granule. Further, the food additive of the present invention includes, for example, for beverages.
- the PPAR activation method of the present invention is, for example, a method comprising bringing ⁇ -cryptoxanthin into contact with fat cells, liver cells and the like.
- the method of activating PPAR of the present invention has, for example, at least one effect such as suppression of secretion of TNF-a and free fatty acids in fat cells, promotion of secretion of adiponectin in fat cells, and promotion of oxidation of fat in liver cells.
- the PPAR activation method of the present invention is, for example, a method for inducing at least one of apoptosis, differentiation and miniaturization of adipocytes.
- the 3 / 3-cributoxanthin used is the same as that used for the PPAR activator of the present invention, for example, citrus, persimmon, papaya, beetle and the like. It is derived from red peppers. Among them, citrus fruits are more preferably derived from mandarin citrus fruits, and particularly preferably derived from Unshu mandarin orange. The raw material can be, for example, whole fruits, and it is particularly preferable to use pulp.
- the method for preventing, treating or ameliorating a disease of the present invention relates to a method for treating insulin, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity in mammals.
- a method for preventing, treating or ameliorating at least one disease selected from the group consisting of administering ⁇ -cributoxanthin examples include a human, a mouse, a rat, a rabbit, a dog, a cat, a rabbit, a pig, a pig, a monkey, and the like.
- the kit of the present invention comprises at least one disease selected from the group consisting of insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity.
- a kit for prevention or treatment comprises at least one disease selected from the group consisting of insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity.
- a second pharmaceutical composition comprising:
- a kit comprising a container for containing the ⁇ cryptoxanthin and the second pharmaceutical composition.
- the use of the present invention may be at least one selected from the group consisting of insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis, and obesity of the present invention in mammals. And the use of cryptoxanthin for the prevention, treatment or amelioration of two diseases.
- the mammal is as described above.
- ⁇ -cributoxanthin in the present invention is preferably produced from citrus fruits as described above.
- An example of this manufacturing method Japanese Patent No. 3359298, is shown below.
- the production of ⁇ -cributoxanthin from citrus fruits can be carried out by a method including the following steps (1) to (4).
- Citrus fruits are squeezed and filtered or sieved.
- Examples of the citrus used in the production method include Unshu mandarin orange, Iyo citrus, summer mikan, Hassaku, bonkan, navel orange, lemon, Valencia orange, grapefruit, and the like.
- Mandarin citrus with a large amount is preferred, more preferably Unshu Mandarin orange.
- the whole citrus fruit can be used as a raw material, but it is particularly preferable to use pulp.
- the citrus fruits are usually squeezed after sorting and washing.
- the juice extractor include an in-line juice extractor, a chopper pulper extractor, and a brown juice extractor.
- the juice obtained is usually contaminated with small pieces of carcinoma skin and coarse pulp, and is filtered or sifted to remove these.
- a paddle type or screw type finisher can be used, and the size of the screen is, for example, 0.3 to 0.5 mm.
- the juice is treated by centrifugation.
- This centrifugation treatment includes light centrifugation and heavy centrifugation under the following conditions.
- the light centrifugation means a level of centrifugation capable of separating large particles of pulp.
- the heavy centrifugation refers to centrifugation at a level at which small particles of pulp can be centrifuged.
- the centrifugal strength of the light centrifugation is, for example, 3000 X g.min or less, and the centrifugal strength of the heavy centrifugation is, for example, 1500 X g- Min, and set the centrifugal strength for light centrifugation to be lower than that for heavy centrifugation.
- the squeezed juice is subjected to light centrifugation, and the supernatant is further subjected to heavy centrifugation to collect a precipitate.
- a solubilized enzyme is added to the precipitate obtained by the heavy centrifugation.
- the solubilizing enzyme for example, actinase, cellulase, hemicellulase, protease, lipase, maceration enzyme, protease, and the like can be used. These enzymes may be used alone or in combination of two or more.
- the addition ratio of the solubilized enzyme is in the range of 0.5 to 10 g per 1 kg of the precipitate.
- the precipitate to which the solubilized enzyme has been added is filled in a container, and frozen without heating. Subsequently, the frozen precipitate is thawed. Thawing may be left at room temperature. The thawed precipitate is subjected to solid-liquid separation and dehydrated by centrifugation to obtain a solid (sediment). This solid content contains a high concentration of ⁇ -cributoxanthin. By repeating the operation of adding purified water to the solid content and centrifuging the solid content, the concentration of the cryptoxanthin in the solid content can be further improved.
- CV-1 cells (cultured cells derived from male African midori kidney kidney) were inoculated into a 24-well culture plate at a concentration of 0.2 zg / well at 37 ° C and 5% CO 2. The cells were cultured under the following conditions for 24 hours.
- DMEM Dulbecco's Modified Eagle Medium: GIBCO
- FBS ⁇ fetal serum
- penicillin'streptomycin solution was used as a medium.
- pM-hPPARy and p4XUASg-tk-luc were transfected into cultured CV-1 cells using a lipofectamine system (Invitrogen).
- the activity of PPARy was improved by ⁇ -tallipoxanthin, and the activity was increased as the concentration of ⁇ -cributoxanthin was increased.
- the PPAR activator of the present invention has excellent PPAR activity, can be taken for a long period of time without any problem of side effects, and can be preferably used for foods and the like. Therefore, the PPAR activator of the present invention is useful for preventing or preventing diseases such as insulin resistance, hyperinsulinemia, type 2 diabetes, hypertension, hyperlipidemia, arteriosclerosis and obesity. Can be used as medicines, supplements, functional foods and food additives for improvement. These are effective not only for humans but also for other animals.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005800160315A CN1956711B (zh) | 2004-05-20 | 2005-05-20 | 过氧化物酶体增殖物激活受体(ppar)活化剂以及使用了该活化剂的药品、补充剂、功能性食品及食品添加剂 |
US11/569,381 US20070218147A1 (en) | 2004-05-20 | 2005-05-20 | Peroxisome Proliferator-Activated Receptor (Ppar) Activator, and Drugs, Supplements, Functional Foods and Food Additives Using the Same |
EP05741624A EP1772143A4 (en) | 2004-05-20 | 2005-05-20 | ACTIVATOR OF PPAR (PEROXISOMEPROLIFERATORACTIVATED RECEPTOR) AND MEDICAMENTS, ADDITIVES, FUNCTIONAL FOODS AND FOOD ADDITIVES USING THIS |
JP2006513743A JPWO2005112904A1 (ja) | 2004-05-20 | 2005-05-20 | ペルオキシソーム増殖剤応答性受容体(ppar)活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-150667 | 2004-05-20 | ||
JP2004150667 | 2004-05-20 | ||
JP2004242653 | 2004-08-23 | ||
JP2004-242653 | 2004-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005112904A1 true WO2005112904A1 (ja) | 2005-12-01 |
Family
ID=35428235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/009258 WO2005112904A1 (ja) | 2004-05-20 | 2005-05-20 | ペルオキシソーム増殖剤応答性受容体(ppar)活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070218147A1 (ja) |
EP (1) | EP1772143A4 (ja) |
JP (3) | JPWO2005112904A1 (ja) |
CN (1) | CN1956711B (ja) |
WO (1) | WO2005112904A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007223979A (ja) * | 2006-02-24 | 2007-09-06 | Ehime Inryo:Kk | 肝臓脂質蓄積抑制剤 |
JP2007223914A (ja) * | 2006-02-21 | 2007-09-06 | Unitika Ltd | 経口投与組成物 |
JP2007246448A (ja) * | 2006-03-16 | 2007-09-27 | Tokyo Univ Of Agriculture & Technology | 歯周病予防・治療剤 |
JP2008297216A (ja) * | 2007-05-29 | 2008-12-11 | Unitika Ltd | 繊維芽細胞増殖促進剤 |
JP2009084192A (ja) * | 2007-09-28 | 2009-04-23 | Unitika Ltd | 体内時計正常化効果を有する組成物 |
WO2009084275A1 (ja) | 2007-12-28 | 2009-07-09 | Unitika Ltd. | 経口投与組成物 |
JP2009161443A (ja) * | 2007-12-28 | 2009-07-23 | Unitika Ltd | 経口投与組成物 |
JP2009179622A (ja) * | 2008-02-01 | 2009-08-13 | Unitika Ltd | 経口投与組成物 |
JP2010202553A (ja) * | 2009-03-02 | 2010-09-16 | Unitika Ltd | レチノイン酸受容体(rar)活性化剤 |
JP2010254592A (ja) * | 2009-04-22 | 2010-11-11 | Ito En Ltd | 脂肪蓄積抑制剤及びそれを含有する飲食品 |
EP2465357A2 (en) | 2010-12-15 | 2012-06-20 | Arkray, Inc. | Stabilized ß cryptoxanthin-containing water and the use thereof |
JP2012206964A (ja) * | 2011-03-29 | 2012-10-25 | Unitika Ltd | PPAR−α活性調節剤 |
JP2014079249A (ja) * | 2013-12-03 | 2014-05-08 | Unitika Ltd | 経口投与組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103110846B (zh) | 2013-02-22 | 2014-07-02 | 嵊州市林美生物科技有限公司 | 一种用于治疗高脂血症的中药组合物及其制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5215660B2 (ja) * | 1974-05-10 | 1977-05-02 | ||
JPH06165651A (ja) | 1991-02-01 | 1994-06-14 | Koopu Foods:Kk | 蜜柑麺の製造方法 |
JP3359298B2 (ja) * | 1998-05-06 | 2002-12-24 | 株式会社愛媛柑橘資源開発研究所 | かんきつ果汁由来のカロチノイド高含有粉末の製造方法 |
JP2000093086A (ja) | 1998-09-18 | 2000-04-04 | Haato & Haato:Kk | 蜜柑入り外郎及びその製造方法 |
TR200202077T2 (tr) * | 1999-03-11 | 2002-11-21 | Nuclear Receptor Research Limited | Prar nükleer reseptörleri için yeni ligandlar |
IL129442A0 (en) * | 1999-04-14 | 2000-02-29 | Lycored Natural Prod Ind Ltd | Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood |
US20050250671A1 (en) * | 2000-04-24 | 2005-11-10 | Yoshihiro Shidoji | Activators of peroxisome proliferator-activated receptor |
JP2004194512A (ja) * | 2002-12-16 | 2004-07-15 | Aritagawa:Kk | ミカン粉末、このミカン粉末を用いた餅菓子 |
JP2004331528A (ja) * | 2003-05-02 | 2004-11-25 | Toyo Seikan Kaisha Ltd | 柿の果実からβ−クリプトキサンチン成分含有抽出物を製造する方法 |
-
2005
- 2005-05-20 EP EP05741624A patent/EP1772143A4/en not_active Ceased
- 2005-05-20 CN CN2005800160315A patent/CN1956711B/zh active Active
- 2005-05-20 WO PCT/JP2005/009258 patent/WO2005112904A1/ja active Application Filing
- 2005-05-20 JP JP2006513743A patent/JPWO2005112904A1/ja active Pending
- 2005-05-20 US US11/569,381 patent/US20070218147A1/en not_active Abandoned
-
2012
- 2012-06-22 JP JP2012140693A patent/JP2012214488A/ja active Pending
-
2014
- 2014-03-31 JP JP2014073014A patent/JP2014122247A/ja active Pending
Non-Patent Citations (4)
Title |
---|
MONTONEN J. ET AL.: "Dietary antioxidant intake and risk of type 2 diabetes.", DIABETES CARE., vol. 27, no. 2, February 2004 (2004-02-01), pages 362 - 366, XP002997077 * |
See also references of EP1772143A4 * |
SUGIURA M. ET AL.: "Nihonsan Kankitsu no Kenko Kinosei.", KAJU KYOKAIHO, vol. 27, no. 2, 2003, pages 39 - 46, XP002997076 * |
TAKAHASHI N. ET AL.: "Dual action of isoprenols from herbal medicines on both PPARY an PPARx in 3T3-L1 adipocytes and HepG2 hepatocytes.", FEBS LETTERS., vol. 514, 2002, pages 315 - 322, XP004347719 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007223914A (ja) * | 2006-02-21 | 2007-09-06 | Unitika Ltd | 経口投与組成物 |
JP2007223979A (ja) * | 2006-02-24 | 2007-09-06 | Ehime Inryo:Kk | 肝臓脂質蓄積抑制剤 |
JP2007246448A (ja) * | 2006-03-16 | 2007-09-27 | Tokyo Univ Of Agriculture & Technology | 歯周病予防・治療剤 |
JP2008297216A (ja) * | 2007-05-29 | 2008-12-11 | Unitika Ltd | 繊維芽細胞増殖促進剤 |
JP2009084192A (ja) * | 2007-09-28 | 2009-04-23 | Unitika Ltd | 体内時計正常化効果を有する組成物 |
JP2009161443A (ja) * | 2007-12-28 | 2009-07-23 | Unitika Ltd | 経口投与組成物 |
WO2009084275A1 (ja) | 2007-12-28 | 2009-07-09 | Unitika Ltd. | 経口投与組成物 |
JP2009179622A (ja) * | 2008-02-01 | 2009-08-13 | Unitika Ltd | 経口投与組成物 |
JP2010202553A (ja) * | 2009-03-02 | 2010-09-16 | Unitika Ltd | レチノイン酸受容体(rar)活性化剤 |
JP2010254592A (ja) * | 2009-04-22 | 2010-11-11 | Ito En Ltd | 脂肪蓄積抑制剤及びそれを含有する飲食品 |
EP2465357A2 (en) | 2010-12-15 | 2012-06-20 | Arkray, Inc. | Stabilized ß cryptoxanthin-containing water and the use thereof |
JP2012206964A (ja) * | 2011-03-29 | 2012-10-25 | Unitika Ltd | PPAR−α活性調節剤 |
JP2014079249A (ja) * | 2013-12-03 | 2014-05-08 | Unitika Ltd | 経口投与組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN1956711A (zh) | 2007-05-02 |
US20070218147A1 (en) | 2007-09-20 |
EP1772143A1 (en) | 2007-04-11 |
CN1956711B (zh) | 2010-06-09 |
JPWO2005112904A1 (ja) | 2008-03-27 |
JP2012214488A (ja) | 2012-11-08 |
JP2014122247A (ja) | 2014-07-03 |
EP1772143A4 (en) | 2009-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005112904A1 (ja) | ペルオキシソーム増殖剤応答性受容体(ppar)活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 | |
JP5473191B2 (ja) | ペルオキシソーム増殖剤応答性受容体(ppar)活性化剤、ならびにそれを用いた医薬、サプリメント、機能性食品および食品添加物 | |
Morisco et al. | Foods and liver health | |
JP5985138B2 (ja) | エネルギー消費促進剤 | |
WO2007029631A1 (ja) | 体内脂質改善組成物 | |
Sung et al. | Nutritional composition and anti-obesity effects of cereal bar containing Allium fistulosum (welsh onion) extract | |
Mostafa | Effect of green tea and green tea rich with catechin on blood glucose levels, serum lipid profile and liver and kidney functions in diabetic rats | |
JP2006335741A (ja) | アモルフォファルス属植物由来ペルオキシソーム増殖剤応答性受容体リガンド組成物 | |
JP2012149004A (ja) | 核内受容体の賦活剤 | |
JP2011148748A (ja) | アディポネクチン分泌促進組成物 | |
WO2011090271A2 (ko) | 여지핵 추출물을 포함하는 지방간 또는 비만의 예방 또는 치료용 조성물 | |
JP2007269631A (ja) | 中性脂肪蓄積抑制剤 | |
JP2013216686A (ja) | ペルオキシソーム増殖剤応答性受容体活性剤および組成物 | |
JP2008231057A (ja) | 中性脂肪吸収調節組成物 | |
JP2010059113A (ja) | ペルオキシソーム増殖剤応答性受容体活性剤および組成物 | |
US11260098B2 (en) | Method for suppressing obesity or development of obesity | |
KR101101808B1 (ko) | 아디픽산의 신규한 용도 | |
JP2011173813A (ja) | PPARα発現促進剤 | |
Laksmitawati et al. | Activity of porang flour and moringa extract to blood glucose and lipid levels in alloxan induced diabetic mice | |
JP5346623B2 (ja) | Ppar活性化剤 | |
JPWO2004045632A1 (ja) | ペルオキシソーム増殖剤応答性受容体リガンド剤 | |
KR101158368B1 (ko) | 은어 단백질 및 펩타이드를 함유하는 항염증 활성용 조성물 및 추출방법 | |
Cogorno et al. | Non-alcoholic fatty liver disease: Dietary and nutraceutical approaches | |
JP5346624B2 (ja) | Ppar活性化剤 | |
JP2009286729A (ja) | アディポネクチン産生促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006513743 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11569381 Country of ref document: US Ref document number: 2007218147 Country of ref document: US Ref document number: 200580016031.5 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2005741624 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005741624 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005741624 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11569381 Country of ref document: US |